Los Angeles Biotechnology Network
  • Home
  • About
  • News
    • All LABN News
    • Trending LABN News
  • Jobs
    • All LABN Jobs
    • Post A Job
  • Subscribe
  • Contact
News Ticker
  • [ March 31, 2023 ] Postdoctoral Fellow – Computational Biology and Molecular Dynamics – City of Hope – Duarte, CA Los Angeles Biotech Jobs
  • [ March 31, 2023 ] QC Microbiology Associate II – B. Braun Medical Inc. – Irvine, CA Los Angeles Biotech Jobs
  • [ March 31, 2023 ] Associate Director, Bioinformatics Engineering, remote – Quest Diagnostics – San Juan Capistrano, CA Los Angeles Biotech Jobs
  • [ March 31, 2023 ] Research Scientist – MicroBio Engineering Inc. – San Luis Obispo, CA Los Angeles Biotech Jobs
  • [ March 31, 2023 ] Quality Control Associate – Microbiology – TechTrueUP – Thousand Oaks, CA Los Angeles Biotech Jobs
HomeLos Angeles Biotech NewsSTAT+: Concerns linger over Cytokinetics, Amgen heart failure drug despite improved study results

STAT+: Concerns linger over Cytokinetics, Amgen heart failure drug despite improved study results

November 13, 2020 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on STAT+: Concerns linger over Cytokinetics, Amgen heart failure drug despite improved study results
Cytokinetics and Amgen presented updated data on a novel drug designed to increase the tension within the muscles of the heart, thereby improving its ability to pump blood.

Click to view original post

Previous

Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update

Next

City of Hope’s Precision Oncology Tumor Board Able to Identify Patients Who May Have Inherited Increased Risk for Colorectal Cancer

Follow/Subscribe

POST A JOB
Tweets by LABioNetwork

Copyright © 2021 Biotech Networks, LLC

Want to Save Time?

Get Trending News & Jobs Delivered